SCHEMBL3002181

SCHEMBL3002181

CC(C)(c1cc(Cl)c(OCCCO)c(Cl)c1)c1cc(Cl)c(OCCCO)c(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.37
PLAU P00749 1/20 0.37
HPGD P15428 3/20 0.36
MAPT P10636 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 6/20 0.35
CYP2C19 P33261 1/20 0.33
GAA P10253 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
S1PR2 O95136 1/20 0.32
S1PR1 P21453 1/20 0.32
S1PR3 Q99500 1/20 0.32
LPAR2 Q9HBW0 1/20 0.32
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
POLB P06746 1/20 0.31
KMT2A Q03164 1/20 0.31
AR P10275 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7045865 0.91 SMN1; SMN2 (0.38) SMN1; SMN2PLAUHPGDMAPTL3MBTL1
SCHEMBL26746294 0.86 KDM4E (0.43) SMN1; SMN2ALDH1A1KDM4EGAATDP1
SCHEMBL26748925 0.86 KDM4E (0.43) SMN1; SMN2ALDH1A1KDM4EGAATDP1
SCHEMBL10990403 0.82 ALDH1A1 (0.53) SMN1; SMN2HPGDALDH1A1KDM4ETDP1
SCHEMBL2999427 0.81 ALDH1A1 (0.39) MAPTALDH1A1KDM4ES1PR1S1PR3
SCHEMBL19484550 0.81 SMN1; SMN2 (0.51) SMN1; SMN2HPGDMAPTALDH1A1KDM4E
SCHEMBL26748898 0.80 AR (0.64) SMN1; SMN2MAPTMAPK1ALDH1A1KDM4E
SCHEMBL26749674 0.80 KDM4E (0.40) SMN1; SMN2HPGDMAPTALDH1A1KDM4E
SCHEMBL2376058 0.79 MAPT (0.54) SMN1; SMN2PLAUHPGDMAPTL3MBTL1
SCHEMBL8997268 0.78 MCL1 (0.47) SMN1; SMN2PLAUL3MBTL1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190812-B1 METHACRYLATE BASED MONOMERS CONTAINING A URETHANE LINKAGE, PROCESS FOR PRODUCTION AND USE THEREOF 3M INNOVATIVE PROPERTIES CO (US) 2015-12-02 EP disclosed
US-8426490-B2 Methacrylate based monomers containing a urethane linkage, process for production and use thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-04-23 US disclosed
US-20100197824-A1 METHACRYLATE BASED MONOMERS CONTAINING A URETHANE LINKAGE, PROCESS FOR PRODUCTION AND USE THEREOF SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2010-08-05 US disclosed
EP-2190812-A1 METHACRYLATE BASED MONOMERS CONTAINING A URETHANE LINKAGE, PROCESS FOR PRODUCTION AND USE THEREOF 3M Innovative Properties Company (US) 2010-06-02 EP disclosed
WO-2009042574-A1 METHACRYLATE BASED MONOMERS CONTAINING A URETHANE LINKAGE, PROCESS FOR PRODUCTION AND USE THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2009-04-02 WO disclosed
EP-2042486-A1 Methacrylate Based Monomers containing a Urethane Linkage, Process for Production and Use thereof 3M Innovative Properties Company (US) 2009-04-01 EP disclosed
US-4525529-A HALOGEN-CONTAINING COPOLYMERIC POLYESTER BLENDED WITH MODIFIED ETHYLENE COPOLYMER MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1985-06-25 US disclosed
US-4454302-A BLEND WITH HALOGEN CONTAINING ACRYLIC RESIN MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) 1984-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197824-A1 METHACRYLATE BASED MONOMERS CONTAINING A URETHANE LINKAGE, PROCESS FOR PRODUCTION AND USE THEREOF PYM1, B2M, MACF1 SMN1; SMN2 3319/4885PLAU 4184/4885HPGD 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.